Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Stella

Home/Multiple Sclerosis (MS) Primary Progressive/A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

View on ClinicalTrials.gov

Recruiting

Back to Multiple Sclerosis (MS) Primary Progressive trials

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(2 sites)

United States

Neurology Associates, PA, Maitland, Florida

Premier Neurology, Greenville, South Carolina

Key details

Phase

Large-scale testing

Sponsor

Zenas BioPharma (USA), LLC

Enrollment target

~705 participants

Started

December 2025

Primary completion

June 2030

Age range

18 Years – 60 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.